Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
- PMID: 15509775
- PMCID: PMC525474
- DOI: 10.1128/MCB.24.22.9695-9704.2004
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
Abstract
PS-341, also known as Velcade or Bortezomib, represents a new class of anticancer drugs which has been shown to potently inhibit the growth and/or progression of human cancers, including head and neck squamous cell carcinoma (HNSCC). Although it has been logically hypothesized that NF-kappaB is a major target of PS-341, the underlying mechanism by which PS-341 inhibits tumor cell growth is unclear. Here we found that PS-341 potently activated the caspase cascade and induced apoptosis in human HNSCC cell lines. Although PS-341 could inhibit NF-kappaB activation, the inhibition of NF-kappaB was not sufficient to initiate apoptosis in HNSCC cells. Using biochemical and microarray approaches, we found that proteasome inhibition by PS-341 induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in HNSCC cells. The inhibition of ROS significantly suppressed caspase activation and apoptosis induced by PS-341. Consistently, PS-341 could not induce the ER stress-ROS in PS-341-resistant HNSCC cells. Taken together, our results suggest that in addition to the abolishment of the prosurvival NF-kappaB, PS-341 might directly induce apoptosis by activating proapoptotic ER stress-ROS signaling cascades in HNSCC cells, providing novel insights into the PS-341-mediated antitumor activity.
Figures







Similar articles
-
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470. Clin Cancer Res. 2008. PMID: 18593997
-
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.Mol Cancer Ther. 2010 Jul;9(7):1977-84. doi: 10.1158/1535-7163.MCT-10-0141. Epub 2010 Jun 22. Mol Cancer Ther. 2010. PMID: 20571067 Free PMC article.
-
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. doi: 10.1016/j.ijrobp.2005.05.007. Epub 2005 Jul 11. Int J Radiat Oncol Biol Phys. 2005. PMID: 16005577
-
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.Semin Oncol. 2001 Dec;28(6):626-33. doi: 10.1016/s0093-7754(01)90036-3. Semin Oncol. 2001. PMID: 11740821 Review.
-
Targeting endoplasmic reticulum signaling pathways in cancer.Acta Oncol. 2012 Sep;51(7):822-30. doi: 10.3109/0284186X.2012.689113. Epub 2012 Jun 11. Acta Oncol. 2012. PMID: 22686473 Review.
Cited by
-
Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity.Mol Biol Cell. 2012 Sep;23(18):3566-81. doi: 10.1091/mbc.E12-03-0192. Epub 2012 Aug 8. Mol Biol Cell. 2012. PMID: 22875985 Free PMC article.
-
Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1.Cell Stress Chaperones. 2012 Nov;17(6):765-78. doi: 10.1007/s12192-012-0349-z. Epub 2012 Jul 13. Cell Stress Chaperones. 2012. PMID: 22791010 Free PMC article.
-
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.Blood. 2010 Jun 3;115(22):4478-87. doi: 10.1182/blood-2009-12-257261. Epub 2010 Mar 16. Blood. 2010. Retraction in: Blood. 2019 Jul 4;134(1):95. doi: 10.1182/blood-2019-05-901223. PMID: 20233973 Free PMC article. Retracted.
-
Characterization of bortezomib-adapted I-45 mesothelioma cells.Mol Cancer. 2010 May 18;9:110. doi: 10.1186/1476-4598-9-110. Mol Cancer. 2010. PMID: 20482802 Free PMC article.
-
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19. Mol Cancer Ther. 2014. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1181. doi: 10.1158/1535-7163.MCT-19-0471. PMID: 25239935 Free PMC article. Retracted.
References
-
- Adams, J. 2003. The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 29(Suppl. 1):3-9. - PubMed
-
- Adams, J., V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Mass, C. S. Pien, S. Prakash, and P. J. Elliot. 1999. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:2615-2622. - PubMed
-
- Chen, S., A. Fribley, and C.-Y. Wang. 2002. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-κB inhibitor. J. Dent. Res. 81:98-102. - PubMed
-
- Fischer, H., U. Koenig, L. Eckhart, and E. Tschachler. 2002. Human caspase 12 has acquired deleterious mutations. Biochem. Biophys. Res. Commun. 293:722-726. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical